Status:
COMPLETED
An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients
Lead Sponsor:
ACADIA Pharmaceuticals Inc.
Conditions:
Parkinson's Disease Psychosis
Eligibility:
All Genders
Phase:
PHASE2
Brief Summary
This is an open-label extension study to assess the long-term safety and tolerability of pimavanserin (ACP-103) in subjects with Parkinson's Disease Psychosis (PDP).
Eligibility Criteria
Inclusion
- Inclusion Criteria-
- Patients of any age, male or female with a clinical diagnosis of idiopathic Parkinson's disease, who participated in a previous (Phase II) clinical trial that evaluated pimavanserin
- Patients who may, in the opinion of the treating physician, benefit from continued therapy with pimavanserin
- Patient is willing and able to provide consent
- Exclusion Criteria-
- Female patient of childbearing potential
- Patient has a clinically significant concurrent medical illness
- Patient is judged by the treating physician to be inappropriate for the study.
Exclusion
Key Trial Info
Start Date :
November 17 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 2 2013
Estimated Enrollment :
39 Patients enrolled
Trial Details
Trial ID
NCT01518309
Start Date
November 17 2004
End Date
May 2 2013
Last Update
November 23 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Danbury, Connecticut, United States, 06810